)
Genomma Lab Internacional (LABB) investor relations material
Genomma Lab Internacional Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 net sales rose 1.3% YoY to MXN 4,497.6m as Latin America growth and Mexico’s continued recovery offset a steep U.S. decline.
Mexico sell-out returned to growth and market share held or improved across business units; new products supported sell-out gains among customers carrying them.
Net income increased 18.6%, supported by lower financing costs and a favorable, non-recurring FX result; promotional and commercial investment pressured margins.
Financial highlights
Q3 net sales were MXN 4,497.6m, up 1.3% YoY; gross profit fell 2.6% to MXN 2,762.1m and gross margin declined to 61.4% from 63.9%.
Operating income fell 10.8% to MXN 863.6m; EBITDA declined 10.3% to MXN 944.9m, with margin at 21.0% versus 23.7%.
Net income rose 18.6% to MXN 514.9m; EPS increased 18.6% to MXN 0.51.
9M net sales declined 3.2% to MXN 13,085.3m and EBITDA fell 11.0% to MXN 2,859.8m, while net income rose 7.5% to MXN 1,384.1m.
Excluding IAS 29 and IAS 21 effects, Q3 net sales declined 6.2%, EBITDA fell 18.8%, and net income increased 20.2% YoY.
Outlook and guidance
Q4 2026 cash conversion cycle expected to decline to ~140 days as Mexican winter inventory sells through and Argentina’s non-cash accounting effect normalizes.
Brazil sell-in expected to normalize in Q1 2027 after customer inventory reductions ahead of the consumption tax reform.
U.S. recovery expected to be gradual; commercial footprint and distribution model are being realigned to stabilize performance.
Q4 2026 and Q1 2027 Cough & Cold launches planned; December 3 Investor Day in New York to present strategy, operating model, execution commitments, and an AI platform.
- Growth driven by innovation, distribution expansion, and rising profitability.LABB
Corporate presentation - Net income rose 5.5% despite a 6.0% sales drop, with gross margin up to 64.6%.LABB
Q2 2026 - Net sales fell 4.9% as FX and weak demand weighed, but LATAM growth and margin gains offset declines.LABB
Q1 2026 - Margins improved to 23.4% despite sales decline, with recovery expected in 2026.LABB
Q4 2025 - EBITDA margin rose to 23.8% and free cash flow surged 65% despite FX headwinds.LABB
Q2 2025 - Q3 2024 delivered double-digit sales and profit growth, margin expansion, and record free cash flow.LABB
Q3 2024 - Q2 2024 saw strong sales, margin expansion, and double-digit EPS growth, driven by M&A and productivity.LABB
Q2 2024 - Q1 2025 saw double-digit EBITDA and EPS growth, with strong cash flow and margin expansion.LABB
Q1 2025 - Double-digit sales, margin, and EPS growth, with record free cash flow and strong regional gains.LABB
Q4 2024
)
)
)
)
)
)
)
)